Sirolimus-eluting Coronary Stent is cost effective vs. bypass surgery

October 20, 2005

WASHINGTON, D.C. OCTOBER 20, 2005 - An independent analysis of a clinical trial comparing the cost-effectiveness of the CYPHER® Sirolimus-eluting Coronary Stent vs. bypass surgery suggests that treatment with the CYPHER® Stent offers a potential cost-savings over bypass surgery. The findings from the Arterial Revascularization Therapy Study (ARTS) I and II were presented today at the annual Transcatheter Cardiovascular Therapeutics (TCT 2005) Conference.

Treatment of multi-vessel coronary artery disease with the CYPHER® Stent was found to be substantially more cost-effective than bypass surgery both during initial hospitalization and at the one-year follow-up.

According to David J. Cohen, M.D., M.Sc., Associate Director of Interventional Cardiology at Beth Israel Deaconess Medical Center in Boston, and Director of Cardiovascular Outcomes Research, Harvard Clinical Research Institute, who presented the results, "These findings provide additional evidence on the benefit of drug-eluting stents in treating complex patient cases that would have been directed to surgery," Dr. Cohen said. "Furthermore, the analysis shows that the economic benefit of the CYPHER® Stent technology is as significant as the clinical benefit we see in these challenging patient cases."

To account for baseline differences, both costs and event rates from ARTS-II were adjusted to reflect the number of a patient's diseased vessels and whether or not the patient had diabetes. Savings related to the avoidance of death, heart attack, revascularization and stroke were examined.

Initial hospitalization costs, accounting for physician fees, room and ancillary charges, and repeat procedures, were $7,700 less (29 percent) for CYPHER® Stent than for CABG, at $26,419 and $34,119 respectively.

Total one-year costs, when adjusted for patient differences in extent of coronary artery disease and diabetes, were $6,487 less (21 percent) for CYPHER® Stent than for CABG, at $30,388 and $36,875 respectively.

ARTS II is a single arm, randomized multi-center trial of 607 patients in 19 countries. The study sample was drawn from the ARTS-I randomized trial (1997-1998) and the ARTS-II registry (2003). Study criteria included patients with multivessel disease who required treatment of at least two major coronary arteries and who had stenoses that would be receptive to stenting.
-end-
About the CYPHER® Stent
The CYPHER® Stent has been chosen by cardiologists worldwide to treat more than 1.5 million patients with coronary artery disease. It is supported by a robust clinical trial program that includes more than 40 studies, inclusive of independent clinical trials, that examine the performance of the stent in vessels of varying complexity. Developed and manufactured by Cordis Corporation, the CYPHER® Stent is currently available in more than 80 countries and has the longest-term clinical follow-up of any drug-eluting stent. The CYPHER SELECTTM Sirolimus-eluting Coronary Stent, which is the first next generation drug-eluting stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. More information about the CYPHER® Stent can be found at www.cypherusa.com.

About The Cordis Corporation
For more than 40 years, Cordis Corporation, a Johnson & Johnson company, has pioneered less invasive treatments for vascular disease. Technological innovation and a deep understanding of the medical marketplace and the needs of patients have made Cordis the world's leading developer and manufacturer of breakthrough products for interventional medicine, minimally invasive computer-based imaging, and electrophysiology. Today, more than 7,000 Cordis employees worldwide share a strong commitment to continue the Company's groundbreaking work in the fight against vascular disease.

Edelman Public Relations

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.